In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

Ixekizumab reduces erosion and increases backfill in the sacroiliac joints of patients with radiographic axial ...

High-parameter flow cytometry of peripheral blood mononuclear cells enabled physicians to treat recalcitrant erythroderma in ...

Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper ...

Discover the 7 warning signs of ulcerative colitis, plus breakthrough treatments and management strategies that can transform ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

A total of 118 recommendations based on expert consensus were published regarding the treatment of hidradenitis suppurativa ...

According to a comprehensive report from The Insight Partners, "Health Economics and Outcome Research (HEOR) Services Market ...